The DESTINY-Breast03 trial provided evidence that trastuzumab deruxtecan offers significant clinical benefits over trastuzumab emtansine for patients with HER2-positive metastatic BC, establishing it as a more effective second-line therapy with a manageable safety profile [77]. This evidence concerns the gene ERBB2 and breast cancer.